EICHORPublic-registry site landscape for NCT06011577, “Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD”, a Major Depressive Disorder study sponsored by Levomecor Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06011577 (registry record) |
| Study title | Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT) |
| Sponsor | Levomecor Inc. |
| Condition(s) | Major Depressive Disorder; Depression |
| Phase | PHASE3 |
| Listed sites | 36 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06011577.
Eichor generates a preliminary site-risk snapshot for NCT06011577 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Major Depressive Disorder trials
← Eichor home · All tracked trials · Major Depressive Disorder studies · Weekly briefs
